Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Hurkmans DP, Sassen SDT, de Joode K, Putter L, Basak EA, Wijkhuijs AJM, Joerger M, Debets R, Koch BCP, Van der Leest CH, Schreurs MWJ, van der Veldt AAM, Aerts JGJV, Mathijssen RHJ, Koolen SLW. Hurkmans DP, et al. Among authors: joerger m. J Immunother Cancer. 2021 Jun;9(6):e002344. doi: 10.1136/jitc-2021-002344. J Immunother Cancer. 2021. PMID: 34088739 Free PMC article.
Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study.
Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich TK, Largiader CR, Joerger M. Mueller F, et al. Among authors: joerger m. Cancer Chemother Pharmacol. 2013 Feb;71(2):361-70. doi: 10.1007/s00280-012-2018-4. Epub 2012 Nov 9. Cancer Chemother Pharmacol. 2013. PMID: 23139054 Free article.
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.
Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim TW, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M. Beumer JH, et al. Among authors: joerger m. Clin Pharmacol Ther. 2019 Mar;105(3):598-613. doi: 10.1002/cpt.1124. Epub 2018 Sep 11. Clin Pharmacol Ther. 2019. PMID: 29923599 Free PMC article. Review.
Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer.
Hoemme A, Barth H, Haschke M, Krähenbühl S, Strasser F, Lehner C, von Kameke A, Wälti T, Thürlimann B, Früh M, Driessen C, Joerger M. Hoemme A, et al. Among authors: joerger m. Cancer Chemother Pharmacol. 2019 Apr;83(4):763-774. doi: 10.1007/s00280-019-03783-9. Epub 2019 Jan 25. Cancer Chemother Pharmacol. 2019. PMID: 30684020 Free article.
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.
Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Del Carmen Gil Cruz C, Pérez Shibayama CI, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser DE, Ludewig B, Levesque MP, Dummer R, Flatz L. Fässler M, et al. Among authors: joerger m. J Immunother Cancer. 2019 Feb 20;7(1):50. doi: 10.1186/s40425-019-0523-2. J Immunother Cancer. 2019. PMID: 30786924 Free PMC article. Clinical Trial.
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients.
Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, Bins S, Hoop EO, Debets R, Joerger M, Odink A, van der Veldt AAM, van der Leest CH, Aerts JGJV, Mathijssen RHJ, Koolen SLW. Hurkmans DP, et al. Among authors: joerger m. J Immunother Cancer. 2019 Jul 19;7(1):192. doi: 10.1186/s40425-019-0669-y. J Immunother Cancer. 2019. PMID: 31324223 Free PMC article.
176 results